Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29989986 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL29591196 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL30074491 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL5323666 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL29792137 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL7423331 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL29350883 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL22069879 | 0.96 | PTPN1 (0.49) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL20732318 | 0.96 | PTPN1 (0.49) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL31133584 | 0.96 | PTPN1 (0.49) | KMT2AMDM4TP53PTPN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116507630-A | PSMA targeted radioactive metal complex containing nitro aromatic heterocyclic group and preparation thereof | 北京师范大学 | 2023-07-28 | — | — | CN | claimed |
| CN-111285780-A | Convergent liquid phase synthesis method of side chain of Somaloutide | 浙江工业大学 | 2020-06-16 | — | — | CN | claimed |
| CN-111269137-A | Method for preparing side chain of Somalutide by liquid phase method | 浙江工业大学 | 2020-06-12 | — | — | CN | claimed |
| CN-111253287-A | Method for synthesizing side chain of Somalutide in liquid phase convergence manner | 浙江工业大学 | 2020-06-09 | — | — | CN | claimed |
| US-20250360186-A1 | DOSAGE REGIMEN FOR INTERLEUKIN-22 DERIVATIVES | CYTOKI PHARMA APS (DK) | 2025-11-27 | — | — | US | disclosed |
| EP-4637803-A2 | DOSAGE REGIMEN FOR INTERLEUKIN-22 DERIVATIVES | Cytoki Pharma ApS (DK) | 2025-10-29 | — | — | EP | disclosed |
| US-12447211-B2 | Therapeutic derivatives of interleukin-22 | CYTOKI PHARMA APS (DK) | 2025-10-21 | — | — | US | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20110213131-A1 | Method of Acylating a Peptide or Protein | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | US | disclosed |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-0737197-B1 | AMINO ALKANOIC ESTERS OF RAPAMYCIN | AMERICAN HOME PROD (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6372883-B1 | FOR THERAPY AND PROPHYLAXIS OF INFECTIONS CAUSED BY HEPATITIS C, HEPATITIS G AND HUMAN GB VIRUSES | HOFFMANN-LA ROCHE INC. | 2002-04-16 | — | — | US | disclosed |
| US-6187905-B1 | PEPTIDE COMPOUND WHICH INHIBITS VIRAL PROTEINASES; VIRICIDES FOR HEPATITIS C, HEPATITIS G, AND HUMAN GB VIRUSES | HOFFMANN-LA ROCHE INC. | 2001-02-13 | — | — | US | disclosed |
| US-6018020-A | VIRICIDES WHICH ARE PROTEASE INHIBITORS AGAINST HEPATITIS C AND HEPATITIS G | HOFFMAN-LA ROCHE INC. (US) | 2000-01-25 | — | — | US | disclosed |
| US-5866684-A | Peptidyl inhibitors of viral proteases | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5389639-A | Immunosuppressants | AMERICAN HOME PRODUCTS COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | KMT2A 4393/4885MDM4 2126/4885TP53 2277/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | KMT2A 2979/4885MDM4 1740/4885TP53 1257/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | KMT2A 1250/4885MDM4 455/4885TP53 8/4885 |
| US-12447211-B2 | Therapeutic derivatives of interleukin-22 | IL2, IL2RA, IL23R | KMT2A 1666/4885MDM4 4252/4885TP53 2388/4885 |
| US-20110213131-A1 | Method of Acylating a Peptide or Protein | DNPEP, PTMA, ANPEP | KMT2A 2645/4885MDM4 2729/4885TP53 2364/4885 |
| US-20250360186-A1 | DOSAGE REGIMEN FOR INTERLEUKIN-22 DERIVATIVES | IL2, FABP2, IL2RA | KMT2A 1972/4885MDM4 4232/4885TP53 3187/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | KMT2A 3145/4885MDM4 441/4885TP53 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.